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BackgroundzzGaucher’s disease is an autosomal recessive, lysosomal storage disease caused by 
mutations of the β-glucocerebrosidase gene (GBA). There is increasing evidence that GBA mu-
tations are a genetic risk factor for the development of Parkinson’s disease (PD). We report herein 
a family of Koreans exhibiting parkinsonism-associated GBA mutations.
Case ReportzzA 44-year-old woman suffering from slowness and paresthesia of the left arm for 
the previous 1.5years, visited our hospital to manage known invasive ductal carcinoma. During 
a preoperative evaluation, she was diagnosed with Gaucher’s disease and double mutations of 
S271G and R359X in GBA. Parkinsonian features including low amplitude postural tremors, ri-
gidity, bradykinesia and shuffling gait were observed. Genetic analysis also revealed that her older 
sister, who had also been diagnosed with PD and had been taking dopaminergic drugs for 8-years, 
also possessed a heterozygote R359X mutation in GBA. 18F-fluoropropylcarbomethoxyiodopheny-
lnortropane positron-emission tomography in these patients revealed decreased uptake of dopamine 
transporter in the posterior portion of the bilateral putamen.
ConclusionszzThis case study demonstrates Korean familial cases of PD with heterozygote 
mutation of GBA, further supporting the association between PD and GBA mutation.
 J Clin Neurol 2011;7:99-101
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Introduction
Gaucher’s disease (GD) is an autosomal recessive, lysosomal 
storage disease that causes abnormal accumulation of a gluco-
cerebroside in multiple organs, as a result of mutations in the 
β-glucocerebrosidase gene (GBA), which is located at chromo-
some 1q21.1 Clinically, GD has a wide spectrum of clinical ma-
nifestations, and the spectrum of the disease tends to be corre-
lated with residual enzyme activity. The most severe form of 
infantile-onset GD presents with widespread accumulation 
of glucosylceramide in a various cell types, leading rapidly to 
fatal neurodegenerative disease, whereas in the late-onset form, 
residual GBA enzyme activity results in highly variable clini-
cal manifestations including hepatosplenomegaly, anemia, 
thrombocytopenia, and skeletal symptoms.1-3
There is increasing evidence that GBA mutations represent 
a genetic risk factor for the development of Parkinson’s disease 
(PD); at autopsy, GD produces α-synuclein-immunoreactive 
Lewy bodies, and parkinsonism appears to be more prevalent 
in relatives of GD patients.3,4 Furthermore, subsequent GBA 
genotyping studies on various PD cohorts have revealed that 
the frequency of GBA mutations is elevated in PD patients. Here 
we present Korean familial cases of PD with heterozygous mu-
tations of GBA, which further supporting the association be-
tween these two disorders.
Case Reports
Patient 1
A 44-year-old woman visited the breast cancer clinic in our 
hospital to manage known invasive ductal carcinoma. Abdo-
men magnetic resonance imaging during a preoperative eva-
luation revealed thrombocytopenia (81,000 platelet/µl) and 
hepatosplenomegaly with four round hypointense nodules. 
In addition, whole body positron emission tomography-com-
puter tomography (PET-CT) revealed bone marrow activa-
tion. At mastectomy, simultaneous bone marrow biopsy of the 
iliac bone was performed to further evaluate the thrombocyto-
penia and marrow abnormality. Immunohistochemical analy-
sis revealed numerous lipid-containing CD-68-positive cells 
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infiltrating the bone marrow (Fig. 1). The patient was then re-
ferred to our neurological department due to slowness and 
paresthesia of the left arm, from which she had been suffering 
for 1.5 years. A family history revealed that she had two bro-
thers and six sisters, and her elder sister had been suffering 
from PD for 8 years. On neurological examination, the pa-
tient’s higher cortical functions were not remarkable, but her 
facial expression was markedly decreased. She had low ampli-
tude postural tremor with a frequency of 4-5 Hz and cogwheel 
rigidities in all 4 limbs. Bradykinesia with fatigability was ob-
served in the bilateral limbs on finger and foot tapping. More-
over, she had a stooped posture and shuffling gait, with decre-
ased bilateral arm swing. These parkinsonian features were 
dominant in the left extremities. Her score on the Unified 
Parkinson’s Disease Rating Scale (UPDRS)-Ш was 22. 
With hematological information, we performed genetic 
analysis of GBA mutations and 18F-fluoropropylcarbometh-
oxyiodophenylnortropane (18F-FP-CIT) PET. This revealed 
compound heterozygous mutations (S271G and R359X) in 
GBA (Fig. 2A) and decreased uptake of dopamine transporter 
in the posterior portion of the bilateral putamen, which was 
more severe on the right side (Fig. 2B). The patient’s parkinso-
nism was considerably improved by the introduction of le-
vodopa medication. (UPDRS-III score 12).
Patient 2
The older sister of previous patient 1, a 55-year-old female, 
had been diagnosed with PD and taking dopaminergic drugs 
for 8-years. On neurological examination, her UPDRS-III sc-
ores during her best on-period was 25, and she exhibited mo-
tor complications of wearing off and peak-dose dyskinesia. 
She had no objective cognitive impairments, as evaluated by a 
detailed neuropsychological evaluation with the Seoul Neu-
ropsychological Screening Battery. 18F-FP-CIT PET revealed 
markedly decreased uptake of dopamine transporter in the po-
sterior portion of the bilateral putamen. Genetic analysis re-
vealed a heterozygous mutation (R359X) in GBA. (Fig. 2A).
Discussion
The neurological symptoms encountered in adult-type GD in-
clude seizures, psychosis, and dementia. However, many case 
reports have suggested indirect evidence of an association be-
tween GD and PD.2,3 McKeran et al.5 reported a 55-year-old 
patient with GD who later developed parkinsonism. Neudor-
fer et al.6 described six patients in whom GD was accompani-
ed by parkinsonism, and Machaczka et al.7 reported another 
patient with parkinsonism that preceded the clinical manifes-
tations of GD by 12-years. Regarding the phenotypical analy-
sis based on large case series, parkinsonism in GD shows clas-
sical symptoms of PD with a tendency toward the akinetic 
form, an early-onset form, and a relatively good response to le-
vodopa.4,8 Furthermore, dementia and visual hallucinations 
are frequently observed in parkinsonism with GD, which may 
be associated with pathological findings, with Lewy bodies 
being observed more frequently in parkinsonism with GD com-
pared to PD on its own.8
Our patients had also exhibited classic parkinsonism with 
Fig. 2. Genetic analysis of GBA and do-
pamine-transporter imaging. Direct po-
lymerase chain reaction sequencing re-
vealed double mutations of S271G (p.
Ser310Gly) and R359X (p.Arg398Term) 
in GBA in patient 1, and the R359X mu-
tation in patient 2 (A). 18F-FP-CIT PET re-
vealed decreased uptake of dopamine 
transporter in the posterior portion of bila-
teral putamen, which was more severe 
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Fig. 1. Immunohistochemical analysis with CD-68 antibodies. Nu-
merous lipid-containing Gaucher cells, which were positive for 
CD-68 staining, have infiltrated the bone marrow.
 Sunwoo MK et al.
www.thejcn.com  101
a young age at onset and an akinetic form, and had an excel-
lent response to levodopa. Even though one patient (a young-
er sister) revealed laboratory abnormalities and pathological 
infiltrations of Gaucher cells, which may be attribute to the 
effects of the S271G/R359X double mutation, these two sis-
ters had no overt clinically systemic manifestations of GD 
except for parkinsonism, as in the case series of heterozygote 
mutation reported previously.8 In addition, the enormous 
clinical variation between genotype and phenotype presenta-
tions in GD may explain the sole clinical manifestation of 
parkinsonism in our cases.9,10 
The association between parkinsonism and the S271G mu-
tation in GBA has also been reported in both Greek and a 
Chinese cohort.11,12 In addition, the R359X mutation in GBA 
found in this study was identified by Beutler and Gelbart in 
non-Jewish patients with GD type 2,13 and its prevalence is re-
ported very low in among Spanish patients with GD.14 How-
ever, the R359X mutation in those reports did not accompany 
a parkinsonian phenotype. Although it is difficult to determine 
which mutation may have impacted the development of a par-
kinsonian phenotype in our patients, since the R359X muta-
tion was found in both patients, the R359X mutation may act 
as a pathogen in the PD phenotype. To our knowledge, this is 
the first report demonstrating the association between parkin-
sonism and the R359X mutation in GBA. The different phe-
notype of the same R359X mutation in GBA may be ascribed 
to racial differences as well as environmental factors influenc-
ing expression of the risk gene. Nevertheless, the pathogenic 
or functional effects of the novel R359X mutation found in 
our PD patients needs to be further clarified. Nevertheless, 
the pathogenic or functional effects of the novel R359X mu-
tation found in our PD patients needs to be further clarified. 
The prevalence of GBA mutations being considered as sus-
ceptibility genes in PD differs with ethnicitys; the carrier freq-
uency of GBA mutations is reportedly 10-31% in the Ashke-
nazi Jewish population and 2.9-12% among the non-Ashken-
azi -Jewish.15 A recent study in a Japanese population found 
that GBA mutations were strikingly associated with PD, ex-
hibiting a markedly high relative risk of 28.0 compared to 
controls.16 Currently, data regarding the association between 
GBA mutations and PD are not available for the Korean pop-
ulation, and future studies of Korean PD patients should com-
pare the prevalence of GBA mutations among Asian PD po-
pulations.
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